Paolo Nuciforo

List of Publications by Year
in descending order

197 papers	11,089 citations	36203 51 h-index	32761 100 g-index
204 all docs	204 docs citations	204 times ranked	19558 citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of *Fusobacterium* persistence and antibiotic response in colorectal cancer. Science, 2017, 358, 1443-1448.	6.0	983
2	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non‑Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-335.	2.4	530
3	Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes and Development, 2006, 20, 3426-3439.	2.7	495
4	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. JAMA Oncology, 2015, 1, 448.	3.4	482
5	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	2.4	469
6	NUMB controls p53 tumour suppressor activity. Nature, 2008, 451, 76-80.	13.7	341
7	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non‑Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research, 2017, 77, 3540-3550.	0.4	327
8	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Annals of Oncology, 2014, 25, 1729-1735.	0.6	308
9	Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature, 2007, 448, 1063-1067.	13.7	296
10	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Annals of Oncology, 2014, 25, 552-563.	0.6	290
11	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Annals of Oncology, 2018, 29, 1203-1210.	0.6	280
12	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncology, The, 2017, 18, 545-554.	5.1	250
13	*PIK3CA* Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2‑Targeted Therapies in Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1334-1339.	0.8	201
14	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Annals of Oncology, 2015, 26, 1280-1291.	0.6	177
15	Brn-2 Represses Microphthalmia-Associated Transcription Factor Expression and Marks a Distinct Subpopulation of Microphthalmia-Associated Transcription Factor‑Negative Melanoma Cells. Cancer Research, 2008, 68, 7788-7794.	0.4	173
16	A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Molecular Medicine, 2018, 10, .	3.3	169
17	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Research, 2017, 77, 2213-2221.	0.4	168
18	The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. Nature Cell Biology, 2009, 11, 133-142.	4.6	154

#	ARTICLE	IF	CITATIONS
19	Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Annals of Oncology, 2017, 28, 1294-1301.	0.6	150
20	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. Nature Communications, 2019, 10, 2416.	5.8	150
21	Tankyrase Inhibition Blocks Wnt/Î²-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 644-656.	3.2	143
22	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature, 2017, 547, 109-113.	13.7	142
23	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget, 2015, 6, 37269-37280.	0.8	135
24	Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell, 2015, 28, 170-182.	7.7	120
25	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. JAMA Oncology, 2017, 3, 227.	3.4	118
26	Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene, 2008, 27, 2148-2158.	2.6	116
27	The Fragile X Protein binds m <scp>RNA</scp> s involved in cancer progression and modulates metastasis formation. EMBO Molecular Medicine, 2013, 5, 1523-1536.	3.3	106
28	Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC). Annals of Oncology, 2017, 28, v605.	0.6	103
29	Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. Journal of Clinical Investigation, 2007, 117, 3436-3444.	3.9	103
30	8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of theFGFR1 andTIF1 genes. Genes Chromosomes and Cancer, 2005, 42, 320-325.	1.5	99
31	FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Annals of Oncology, 2019, 30, 1289-1297.	0.6	97
32	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. Journal of the National Cancer Institute, 2020, 112, 46-54.	3.0	97
33	Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. Oncogene, 2009, 28, 2959-2968.	2.6	96
34	Prognostic Value of Intrinsic Subtypes in Hormone Receptorâ€"Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. JAMA Oncology, 2016, 2, 1287.	3.4	96
35	An Atlas of Altered Expression of Deubiquitinating Enzymes in Human Cancer. PLoS ONE, 2011, 6, e15891.	1.1	88
36	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Annals of Oncology, 2018, 29, 170-177.	0.6	84

#	Article	IF	Citations
37	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget, 2016, 7, 56295-56308.	0.8	83
38	Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Annals of Oncology, 2020, 31, 1366-1375.	0.6	80
39	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clinical Cancer Research, 2016, 22, 560-566.	3.2	79
40	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. Journal of Clinical Investigation, 2018, 128, 3887-3905.	3.9	79
41	High HER2 protein levels correlate with increased survival in breast cancer patients treated with antiâ€HER2 therapy. Molecular Oncology, 2016, 10, 138-147.	2.1	76
42	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2019, 20, 1226-1238.	5.1	76
43	Gene expression analysis of early and advanced gastric cancers. Oncogene, 2007, 26, 4284-4294.	2.6	75
44	CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 782-786.	1.4	73
45	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. Clinical Cancer Research, 2015, 21, 569-576.	3.2	71
46	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. Clinical Cancer Research, 2020, 26, 5820-5829.	3.2	68
47	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. Nature Communications, 2020, 11, 385.	5.8	67
48	Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. Journal of Clinical Investigation, 2021, 131, .	3.9	66
49	Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. Journal of Autoimmunity, 2019, 103, 102285.	3.0	62
50	A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell and Melanoma Research, 2011, 24, 326-333.	1.5	60
51	PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clinical Cancer Research, 2015, 21, 2065-2074.	3.2	59
52	p95HER2â€"T cell bispecific antibody for breast cancer treatment. Science Translational Medicine, 2018, 10, .	5.8	59
53	DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Annals of Oncology, 2017, 28, 2451-2457.	0.6	58
54	Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals of Oncology, 2017, 28, 128-135.	0.6	54

#	ARTICLE	IF	CITATIONS
55	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology, 2021, 299, 109-119.	3.6	54
56	Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR Ã— LGR5 bispecific antibody with efficacy in epithelial tumors. Nature Cancer, 2022, 3, 418-436.	5.7	46
57	Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. Annals of Oncology, 2008, 19, 1875-1881.	0.6	45
58	Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Scientific Reports, 2013, 3, 3544.	1.6	45
59	Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy. JCO Precision Oncology, 2018, 2018, 1-15.	1.5	45
60	Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nature Communications, 2021, 12, 1503.	5.8	45
61	Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS ONE, 2015, 10, e0129876.	1.1	45
62	Early evolutionary divergence between papillary and anaplastic thyroid cancers. Annals of Oncology, 2018, 29, 1454-1460.	0.6	44
63	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel *HER2* V659E Mutation. Cancer Discovery, 2013, 3, 1238-1244.	7.7	43
64	Lymphomas of the Bone: A Pathological and Clinical Study of 54 Cases. International Journal of Surgical Pathology, 2002, 10, 257-266.	0.4	42
65	Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system. Journal of Clinical Pathology, 2013, 66, 124-135.	1.0	42
66	Prep1 (pKnox1)â€‘deficiency leads to spontaneous tumor development in mice and accelerates EÎ¼Myc lymphomagenesis: A tumor suppressor role for Prep1. Molecular Oncology, 2010, 4, 126-134.	2.1	41
67	Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. Journal of Experimental Medicine, 2018, 215, 1913-1928.	4.2	41
68	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cellâ€"like phenotype. Science Translational Medicine, 2020, 12, .	5.8	40
69	Preclinical *In Vivo* Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Research, 2022, 82, 1646-1657.	0.4	40
70	DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 341-345.	0.6	39
71	Quantification of HER family receptors in breast cancer. Breast Cancer Research, 2015, 17, 53.	2.2	39
72	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. Molecular Oncology, 2014, 8, 150-158.	2.1	37

#	Article	IF	Citations
73	A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Annals of Oncology, 2019, 30, 927-933.	0.6	37
74	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. Journal of the National Cancer Institute, 2014, 106, .	3.0	36
75	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget, 2018, 9, 20617-20630.	0.8	36
76	Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Annals of Oncology, 2015, 26, 1494-1500.	0.6	35
77	Monoclonal Antibodies against the Human Somatostatin Receptor Subtypes 1â€"5: Development and Immunohistochemical Application in Neuroendocrine Tumors. Neuroendocrinology, 2012, 95, 232-247.	1.2	34
78	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. International Journal of Molecular Sciences, 2020, 21, 1386.	1.8	33
79	Pirin Inhibits Cellular Senescence in Melanocytic Cells. American Journal of Pathology, 2011, 178, 2397-2406.	1.9	31
80	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clinical Cancer Research, 2020, 26, 738-745.	3.2	31
81	Tumor-Associated Microbiome: Where Do We Stand?. International Journal of Molecular Sciences, 2021, 22, 1446.	1.8	31
82	LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells. Oncogene, 2020, 39, 79-121.	2.6	28
83	Analysis of mutant allele fractions in driver genes in colorectal cancer â€" biological and clinical insights. Molecular Oncology, 2017, 11, 1263-1272.	2.1	26
84	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. Npj Precision Oncology, 2021, 5, 23.	2.3	26
85	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. Oncologist, 2019, 24, 893-900.	1.9	25
86	ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma. Clinical Cancer Research, 2022, 28, 1662-1671.	3.2	25
87	First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. European Journal of Cancer, 2017, 81, 142-150.	1.3	24
88	Molecular profiling of longâ€term responders to immune checkpoint inhibitors in advanced nonâ€small cell lung cancer. Molecular Oncology, 2021, 15, 887-900.	2.1	24
89	Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of antiâ€"<i>Salmonella typhimurium</i> immunity. Journal of Experimental Medicine, 2008, 205, 657-667.	4.2	22
90	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clinical Cancer Research, 2020, 26, 3720-3731.	3.2	21

#	Article	IF	Citations
91	Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 993-1003.	3.2	21
92	Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. Regulatory Peptides, 2013, 187, 35-41.	1.9	19
93	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by *TP53* Mutation in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5499-5510.	3.2	18
94	Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. Journal of the National Cancer Institute, 2018, 110, 914-917.	3.0	16
95	Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Scientific Reports, 2019, 9, 13568.	1.6	14
96	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. JAMA Oncology, 2018, 4, e181564.	3.4	13
97	Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2022, 114, 467-470.	3.0	13
98	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. British Journal of Cancer, 2021, 124, 1581-1591.	2.9	12
99	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. Clinical Cancer Research, 2021, 27, 6156-6163.	3.2	12
100	High *FGFR1–4* mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clinical Cancer Research, 2022, 28, 137-149.	3.2	12
101	Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. Molecular Cancer Therapeutics, 2020, 19, 1289-1297.	1.9	11
102	A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway. Molecular Cancer Therapeutics, 2021, 20, 2250-2261.	1.9	11
103	Performance of 16S Metagenomic Profiling in Formalin-Fixed Paraffin-Embedded versus Fresh-Frozen Colorectal Cancer Tissues. Cancers, 2021, 13, 5421.	1.7	11
104	Malakoplakia of the pancreas with diffuse lymph-node involvement. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 442, 82-85.	1.4	10
105	Abstract PD3-03: SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer. Cancer Research, 2019, 79, PD3-03-PD3-03.	0.4	10
106	The search for simplicity: is this compatible with precision medicine?. Annals of Oncology, 2017, 28, 10-12.	0.6	9
107	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. Npj Breast Cancer, 2021, 7, 145.	2.3	9
108	Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. Cellular Oncology (Dordrecht), 2015, 38, 39-48.	2.1	8

#	Article	IF	Citations
109	Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open, 2019, 4, e000444.	2.0	8
110	Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. Molecular Cancer Therapeutics, 2020, 19, 312-317.	1.9	8
111	Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer. Breast, 2020, 53, 102-110.	0.9	8
112	Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. European Journal of Radiology, 2020, 133, 109345.	1.2	8
113	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clinical Cancer Research, 2021, 27, 6307-6313.	3.2	8
114	On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.. Journal of Clinical Oncology, 2019, 37, 574-574.	0.8	8
115	The Porto European Cancer Research Summit 2021. Molecular Oncology, 2021, 15, 2507-2543.	2.1	7
116	First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.. Journal of Clinical Oncology, 2018, 36, TPS2619-TPS2619.	0.8	7
117	Concordance of genomic alterations (GA) in synchronous tumor biopsies (tBx) and circulating tumor (ct) DNA from metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2018, 36, 1073-1073.	0.8	7
118	Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial. Annals of Oncology, 2017, 28, v46.	0.6	6
119	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. Journal of Clinical Oncology, 2019, 37, 571-571.	0.8	6
120	PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial. European Journal of Cancer, 2018, 92, S117-S118.	1.3	5
121	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clinical Cancer Research, 2021, 27, 5607-5618.	3.2	5
122	Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial. , 2018, , .		5
123	Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. British Journal of Cancer, 2021, 125, 1561-1569.	2.9	4
124	Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial. Cancer Research, 2018, 78, P5-20-19-P5-20-19.	0.4	4
125	Abstract 5129:Fusobacteriumand co-occurring microbes in primary and metastatic colorectal cancer. , 2018, , .		3
126	Abstract P1-09-09: Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer. , 2017, , .		3

#	Article	IF	Citations
127	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. Journal of Clinical Oncology, 2018, 36, 1025-1025.	0.8	3
128	Measuring the impact of Next Generation Sequencing (NGS) technique implementation in metastatic colorectal cancer (mCRC) drug development program.. Journal of Clinical Oncology, 2015, 33, 3598-3598.	0.8	3
129	Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, 528-528.	0.8	3
130	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Frontiers in Oncology, 2021, 11, 744112.	1.3	3
131	PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors. Annals of Oncology, 2019, 30, v760.	0.6	2
132	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. Npj Breast Cancer, 2021, 7, 73.	2.3	2
133	1107P Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601). Annals of Oncology, 2021, 32, S914-S915.	0.6	2
134	Matching degree between PI3K/AKT/mTOR (PAM) pathway mutations (mut) and therapy (ttx) as predictor of clinical benefit (ClinBen) in early trials.. Journal of Clinical Oncology, 2016, 34, 2572-2572.	0.8	2
135	Patient-derived AVATAR mouse models to predict prognosis in advanced renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 551-551.	0.8	2
136	Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1075-1075.	0.8	2
137	Abstract P6-01-06: Feasibility of the PROSIGNA® multigene test in core biopsies and comparison to corresponding surgical breast cancer sections. Cancer Research, 2015, 75, P6-01-06-P6-01-06.	0.4	2
138	Immune profile and outcomes of patients (pts) with gynecological malignancies (GYN) enrolled in early phases immunotherapy (IO) trials.. Journal of Clinical Oncology, 2018, 36, 5595-5595.	0.8	2
139	Lurbinectedin (PM01183) exhibits antitumor activity in PARP-inhibitor resistant germline BRCA PDX and lacks cross-resistance with cisplatin. Annals of Oncology, 2016, 27, vi526.	0.6	1
140	Prognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC). Annals of Oncology, 2017, 28, v143-v144.	0.6	1
141	FGFR 360° resistance: Establishing a translational research framework in FGFR-altered (FGFRalt) patients (pt) treated with fibroblast growth factor receptor inhibitors (FGFRinh). Annals of Oncology, 2017, 28, v575.	0.6	1
142	AGATA molecular screening program: Implementing precision medicine in patients with advanced breast cancer in Spain. Annals of Oncology, 2017, 28, v104-v105.	0.6	1
143	RNF43- and NOTCH1-Mutated Chemotherapy and Anti–EGFR-Refractory Colorectal Cancer: Should Clonality Guide Target Prioritization With Investigational Therapies?. JCO Precision Oncology, 2019, 3, 1-3.	1.5	1
144	Immunohistochemistry protocol for Î³H2AX detection (formalin-fixed paraffin-embedded sections). Protocol Exchange, 0, , .	0.3	1

#	Article	IF	Citations
145	Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.. Journal of Clinical Oncology, 2014, 32, 649-649.	0.8	1
146	Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. Journal of Clinical Oncology, 2019, 37, 1050-1050.	0.8	1
147	Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term benefit to immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2019, 37, 9071-9071.	0.8	1
148	Abstract S3-03: PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial. Cancer Research, 2017, 77, S3-03-S3-03.	0.4	1
149	Impact of early trials in molecularly-characterized patients (pts) with head and neck cancer (HNC).. Journal of Clinical Oncology, 2017, 35, 6031-6031.	0.8	1
150	Impact of genomic heterogeneity on PI3K/AKT/mTOR inhibitors (PAMi) efficacy in gynecologic cancer (GYN) patients (pts).. Journal of Clinical Oncology, 2017, 35, 5569-5569.	0.8	1
151	RNAseq analysis of the sorafenib phase III DECISION trial in differentiated thyroid cancer (DTC): Correlation with clinical outcome.. Journal of Clinical Oncology, 2017, 35, 6083-6083.	0.8	1
152	Abstract 2088: The activity of the FGFR selective inhibitor Debio 1347 is correlated with high mRNA expression. , 2017, , .		1
153	Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast. Journal of Immunotherapy and Precision Oncology, 2019, 2, 130-136.	0.6	1
154	Abstract P4-10-23: Expression of PD-L1 is independent of PIK3CA/AKT1/PTEN alterations in triple-negative breast cancer (TNBC) and is not associated with response to ipatasertib (IPAT) plus paclitaxel (PAC). , 2020, , .		1
155	Abstract P2-13-12: High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study. Cancer Research, 2022, 82, P2-13-12-P2-13-12.	0.4	1
156	Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC). Cancer Research, 2022, 82, P1-07-02-P1-07-02.	0.4	1
157	ecancermedicalscience. Ecancermedicalscience, 2010, 4, 183.	0.6	0
158	The Fragile X Protein binds mRNA s involved in cancer progression and modulates metastasis formation. EMBO Molecular Medicine, 2014, 6, 567-568.	3.3	0
159	303: A role for senescent cell-derived IL6 in HER2+ breast cancer progression. European Journal of Cancer, 2014, 50, S72.	1.3	0
160	2399 Impact of KRAS mutations on clinical outcomes in advanced refractory pancreatic cancer patients. European Journal of Cancer, 2015, 51, S470.	1.3	0
161	O-024 Circulating tumor DNA extended RAS mutational analysis as a surrogate of mutational status of tumor samples in metastatic colorectal cancer and its impact on patient selection for anti-EGFR therapy. Annals of Oncology, 2016, 27, ii127.	0.6	0
162	Prognostic impact of KRAS mutation in metastatic (met) pancreatic cancer patients (pts). Annals of Oncology, 2016, 27, vi232.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ). Annals of Oncology, 2016, 27, vi213.	0.6	0
164	Different RNA expression profile defines prognosis in grade 1/2 neuroendocrine neoplasms of small intestine origin: The GETNE-NETSEQ study. Annals of Oncology, 2017, 28, v143.	0.6	0
165	First-in-human study of AMC303 as monotherapy in patients with advanced solid tumor of epithelial origin. Annals of Oncology, 2017, 28, v141.	0.6	0
166	Tumor-infiltrating lymphocytes density correlates with HER2 gene copy number but not with protein levels in HER2-positive breast cancer. European Journal of Cancer, 2018, 92, S128.	1.3	0
167	Development and validation of neuroendocrine tumor marker panel in small biopsies using multiplexed mass spectrometry. Annals of Oncology, 2018, 29, viii476.	0.6	0
168	Mutational profile applicability in the prognosis of resected colorectal liver metastases beyond the classical clinical risk score. Hpb, 2018, 20, S351.	0.1	0
169	Adapting a prescreening program to match molecular alterations in over 5,000 patients' tumors with targeted agents and immunotherapies in early clinical trials over the last 8 years. Annals of Oncology, 2018, 29, vi23.	0.6	0
170	Analysis of mismatch repair (MMR) genes and pd-l1 expression in invasive micropapillary carcinoma of the breast (IMPCS). European Journal of Cancer, 2018, 92, S122-S123.	1.3	0
171	RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer. Annals of Oncology, 2019, 30, v217.	0.6	0
172	Molecular subtypes of metastatic (met) gastric cancer (GC) (MoTriGastric): New biomarkers closer to the clinics. Annals of Oncology, 2019, 30, v315.	0.6	0
173	581P VHIO immune gene expression profiling (VIGex) panel, a tool to explore tumour immune microenvironment. Annals of Oncology, 2020, 31, S492-S493.	0.6	0
174	562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex. Annals of Oncology, 2020, 31, S484-S485.	0.6	0
175	P-112 Compliance analysis of biological samples and questionnaire collection in a colorectal cancer microbiome study: The VHIO experience. Annals of Oncology, 2021, 32, S137.	0.6	0
176	Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti–Salmonella typhimuriumimmunity. Journal of Cell Biology, 2008, 180, i17-i17.	2.3	0
177	Inflammatory pseudo bladder tumour: Clinical case. Urologia, 1997, 64, 430-433.	0.3	0
178	Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 3591-3591.	0.8	0
179	Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d'Hebron Institute of Oncology phase I program cohort.. Journal of Clinical Oncology, 2015, 33, 587-587.	0.8	0
180	Abstract 4784: FGFR-selective inhibitor Debio 1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models. , 2016, , .		0

#	Article	IF	Citations
181	Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers. , 2016, , .		0
182	Estrogen receptor and human epidermal growth factor receptor-2 quantification and efficacy to trastuzumab. Translational Cancer Research, 2016, 5, S569-S571.	0.4	0
183	Molecular markers to predict response to selective fibroblast growth factor receptor inhibitors (FGFRinh) in patients (pts) with FGFR-amplified (amp) or mutated (mut) tumors.. Journal of Clinical Oncology, 2017, 35, 2581-2581.	0.8	0
184	Molecular sequencing and gene fusion detection in non-small cell lung cancer (NSCLC) patients: Impact of co-existing alterations.. Journal of Clinical Oncology, 2017, 35, e23103-e23103.	0.8	0
185	Abstract B075: Evolving molecular prescreening program to identify genomic alterations in the NOTCH pathway. , 2018, , .		0
186	Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial. , 2018, , .		0
187	Abstract P2-09-14: A predictive model of pathological response following dual HER2 blockade-only based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer. , 2018, , .		0
188	Abstract P2-09-01: T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial. , 2018, , .		0
189	Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer. , 2018, , .		0
190	Real-world data on overall survival (OS) impact of anti-EGFR sequence in patients (pts) with microsatellite stable (MSS) all-RAS and BRAFV600E wild-type metastatic (met) colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 3551-3551.	0.8	0
191	Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome dataTranslating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.. Journal of Clinical Oncology, 2018, 36, 4071-4071.	0.8	0
192	Abstract LB-292: p95HER2-T cell bispecific antibody for breast cancer treatment. , 2018, , .		0
193	Abstract 4881: Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347. , 2019, , .		0
194	Abstract 4891: Gene expression analysis of paired baseline (BL) and on-treatment tumor samples from FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) in early triple-negative breast cancer (eTNBC). , 2019, , .		0
195	The predictive role of plasma mutant allele fraction to antiangiogenic drugs in patients with mCRC: An expanded analysis of surrogate biomarkers of response to first-line treatment with bevacizumab.. Journal of Clinical Oncology, 2020, 38, 3541-3541.	0.8	0
196	Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.. Journal of Clinical Oncology, 2020, 38, 511-511.	0.8	0
197	Abstract 1998: Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial. , 2020, , .		0